Loading…
Loading…
EQUITY / NASDAQ · XNMS
ImmunoPrecise Antibodies Ltd.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →05/01/2024 – 04/30/2025 · CAD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.34 USD · 0%
Observed: Oct 2, 2026, 9:12 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 1.34 USD · Volume 96,146
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
3 available financial reports
Research reports →SEC FINANCIAL REPORTS
05/01/2024 – 04/30/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Revenue | 24,520,000 CAD | 24,518,000 CAD | +0.01% |
| Net income | -30,234,000 CAD | -26,115,000 CAD | — |
| Operating cash flow | -6,410,000 CAD | -3,184,000 CAD | — |
| Cash and cash equivalents | 10,791,000 CAD | 3,545,000 CAD | +204.40% |
| Total liabilities | 20,815,000 CAD | 24,310,000 CAD | -14.38% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end05/01/2024 – 04/30/2025ConsolidatedUnits · CAD | 2024 / Year end05/01/2023 – 04/30/2024ConsolidatedUnits · CAD | 2023 / Year end05/01/2022 – 04/30/2023ConsolidatedUnits · CAD |
|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 10,791,000 CAD | 3,545,000 CAD | 8,366,000 CAD |
| Financing cash flowCash flow statement | 14,893,000 CAD | 1,021,000 CAD | -621,000 CAD |
| Gross profitIncome statement | 13,548,000 CAD | 12,053,000 CAD | 11,563,000 CAD |
| Investing cash flowCash flow statement | -799,000 CAD | -1,563,000 CAD | -1,967,000 CAD |
| Net incomeIncome statement | -30,234,000 CAD | -26,115,000 CAD | -26,560,000 CAD |
| Operating cash flowCash flow statement | -6,410,000 CAD | -3,184,000 CAD | -19,833,000 CAD |
| RevenueIncome statement | 24,520,000 CAD | 24,518,000 CAD | 20,665,000 CAD |
| Total assetsBalance sheet | 44,441,000 CAD | 59,988,000 CAD | — |
| Total equityBalance sheet | 23,626,000 CAD | 35,678,000 CAD | 58,511,000 CAD |
| Total liabilitiesBalance sheet | 20,815,000 CAD | 24,310,000 CAD | — |
| Report source | Open report ↗ Published: 07/29/2025 | Open report ↗ Published: 07/29/2025 | Open report ↗ Published: 07/29/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.